<p>爱国者金融集团保险代理公司在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股比例提高了 184.6%。该基金在此期间购买了 9,242 股后，持有该公司 14,249 股股票。爱国者金融集团保险代理公司在艾伯维的持股在最近一个季度末价值为 3,299,000 美元。</p>
<ul>
<li>3 只分析师看好的 2026 年股息增长股票</li>
</ul>
<p>其他机构投资者最近也增加或减少了在该公司的持股。霍巴特私人资本公司在第三季度将其在艾伯维的股份增加了 4.4%。霍巴特私人资本公司现在拥有 1,127 股该公司的股票，价值 261,000 美元，此前在此期间又购买了 48 股。Rise Advisors LLC 在第三季度将其在艾伯维的持股增加了 3.4%。Rise Advisors LLC 现在拥有 1,451 股该公司的股票，价值 336,000 美元，此前在此期间又购买了 48 股。Sivia Capital Partners LLC 在第二季度将其在艾伯维的持股增加了 1.1%。Sivia Capital Partners LLC 现在拥有 4,571 股该公司的股票，价值 848,000 美元，此前在上个季度又购买了 51 股。FF Advisors LLC 在第二季度将其在艾伯维的持股增加了 3.6%。FF Advisors LLC 现在拥有 1,539 股该公司的股票，价值 286,000 美元，此前在此期间又购买了 53 股。最后，Landaas &amp; Co. WI ADV 在第二季度将其在艾伯维的持股增加了 1.1%。Landaas &amp; Co. WI ADV 现在拥有 4,955 股该公司的股票，价值 920,000 美元，此前在此期间又购买了 53 股。对冲基金和其他机构投资者持有该公司 70.23% 的股票。</p>
<h2>艾伯维股票表现</h2>
<p>艾伯维股票周五开盘价为 222.87 美元。该公司的市值为 3938.9 亿美元，市盈率为 168.84，市盈增长比率为 1.27，贝塔值为 0.36。该公司的 50 日简单移动平均线为 226.70 美元，200 日简单移动平均线为 210.69 美元。艾伯维公司的一年最低价为 164.39 美元，一年最高价为 244.81 美元。该公司的债务与股本比率为 44.14，速动比率为 0.60，流动比率为 0.72。</p>
<ul>
<li>股息强劲：3 只适合长期投资的蓝筹股</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 10 月 31 日发布了季度财报。该公司报告每股收益为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。艾伯维的净利润率为 4.00%，股本回报率为 3,216.47%。该公司在本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。去年同期，该公司的每股收益为 3.00 美元。与去年同期相比，该公司的收入增长了 9.1%。艾伯维已将 2025 年第四季度的指导目标设定为每股收益 3.320-3.360 美元。研究分析师预计艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
<h2>艾伯维增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得 1.73 美元的股息。这比艾伯维之前的季度股息 1.64 美元有所增加。这代表着每年 6.92 美元的股息，收益率为 3.1%。该股息的除息日期为 1 月 16 日（星期五）。艾伯维的股息支付比率目前为 496.97%。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
<p>艾伯维最近成为多份研究报告的主题。DZ 银行将艾伯维的评级从 “买入” 下调至 “持有”，并设定了 237.00 美元的股票目标价。在 11 月 4 日（星期二）的研究报告中。花旗集团将艾伯维的目标价从 240.00 美元下调至 235.00 美元，并在 11 月 3 日（星期一）的研究报告中对该公司给予 “中性” 评级。BMO 资本市场将艾伯维的目标价从 215.00 美元上调至 240.00 美元，并在 9 月 12 日（星期五）的报告中给予该股票 “跑赢大盘” 评级。Erste 集团银行在 10 月 14 日（星期二）的报告中将艾伯维的评级从 “买入” 下调至 “持有”。最后，摩根大通将艾伯维的目标价从 250.00 美元上调至 260.00 美元，并在 11 月 3 日（星期一）的研究报告中给予该股票 “增持” 评级。三位分析师对该股票给予 “强烈买入” 评级，十三位给予 “买入” 评级，八位对该公司的股票给予 “持有” 评级。根据 MarketBeat.com，该股票目前的平均评级为 “适度买入”，共识目标价为 245.84 美元。</p>
<p><strong>查看我们对艾伯维的最新分析</strong></p>
<h2>关于艾伯维</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过艾伯维</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>投资石油股票的方式和原因</li>
<li>忘掉芯片：4 只工业股在人工智能反弹中的表现</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
<p><strong>想知道其他对 ABBV 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 AbbVie Inc. (NYSE:ABBV - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 AbbVie 吗？</h2>
<p>在考虑 AbbVie 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 AbbVie 并不在名单上。</p>
<p>虽然 AbbVie 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>爱国者金融集团保险代理公司在第三季度将其在艾伯维的股份增加了 184.6%，目前持有 14,249 股，价值 3,299,000 美元。其他机构投资者也调整了他们的持股。艾伯维报告第三季度每股收益为 1.86 美元，超出预期，营收同比增长 9.1%。该公司将季度股息提高至每股 1.73 美元。分析师对艾伯维的评级不一，有的下调评级，有的则提高了目标价</p>

<p>Patriot Financial Group Insurance Agency LLC lifted its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 184.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,249 shares of the company's stock after purchasing an additional 9,242 shares during the period. Patriot Financial Group Insurance Agency LLC's holdings in AbbVie were worth $3,299,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>爱国者金融集团保险代理公司在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股比例提高了 184.6%。该基金在此期间购买了 9,242 股后，持有该公司 14,249 股股票。爱国者金融集团保险代理公司在艾伯维的持股在最近一个季度末价值为 3,299,000 美元。</p>
</div><ul>
<li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只分析师看好的 2026 年股息增长股票</li>
</ul>
</div><p>Other institutional investors also recently added to or reduced their stakes in the company. Hobart Private Capital LLC increased its position in shares of AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company's stock worth $261,000 after acquiring an additional 48 shares during the period. Rise Advisors LLC boosted its holdings in shares of AbbVie by 3.4% in the third quarter. Rise Advisors LLC now owns 1,451 shares of the company's stock valued at $336,000 after purchasing an additional 48 shares during the period. Sivia Capital Partners LLC grew its stake in AbbVie by 1.1% in the second quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company's stock worth $848,000 after purchasing an additional 51 shares in the last quarter. FF Advisors LLC increased its holdings in AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company's stock worth $286,000 after purchasing an additional 53 shares during the period. Finally, Landaas &amp; Co. WI ADV increased its holdings in AbbVie by 1.1% during the 2nd quarter. Landaas &amp; Co. WI ADV now owns 4,955 shares of the company's stock worth $920,000 after purchasing an additional 53 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也增加或减少了在该公司的持股。霍巴特私人资本公司在第三季度将其在艾伯维的股份增加了 4.4%。霍巴特私人资本公司现在拥有 1,127 股该公司的股票，价值 261,000 美元，此前在此期间又购买了 48 股。Rise Advisors LLC 在第三季度将其在艾伯维的持股增加了 3.4%。Rise Advisors LLC 现在拥有 1,451 股该公司的股票，价值 336,000 美元，此前在此期间又购买了 48 股。Sivia Capital Partners LLC 在第二季度将其在艾伯维的持股增加了 1.1%。Sivia Capital Partners LLC 现在拥有 4,571 股该公司的股票，价值 848,000 美元，此前在上个季度又购买了 51 股。FF Advisors LLC 在第二季度将其在艾伯维的持股增加了 3.6%。FF Advisors LLC 现在拥有 1,539 股该公司的股票，价值 286,000 美元，此前在此期间又购买了 53 股。最后，Landaas &amp; Co. WI ADV 在第二季度将其在艾伯维的持股增加了 1.1%。Landaas &amp; Co. WI ADV 现在拥有 4,955 股该公司的股票，价值 920,000 美元，此前在此期间又购买了 53 股。对冲基金和其他机构投资者持有该公司 70.23% 的股票。</p>
</div><h2>AbbVie Stock Performance</h2>
<div class="lb-trans"><h2>艾伯维股票表现</h2>
</div><p>Shares of AbbVie stock opened at $222.87 on Friday. The company has a market capitalization of $393.89 billion, a PE ratio of 168.84, a P/E/G ratio of 1.27 and a beta of 0.36. The company has a 50-day simple moving average of $226.70 and a two-hundred day simple moving average of $210.69. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72.</p>
<div class="lb-trans"><p>艾伯维股票周五开盘价为 222.87 美元。该公司的市值为 3938.9 亿美元，市盈率为 168.84，市盈增长比率为 1.27，贝塔值为 0.36。该公司的 50 日简单移动平均线为 226.70 美元，200 日简单移动平均线为 210.69 美元。艾伯维公司的一年最低价为 164.39 美元，一年最高价为 244.81 美元。该公司的债务与股本比率为 44.14，速动比率为 0.60，流动比率为 0.72。</p>
</div><ul>
<li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li>
</ul>
<div class="lb-trans"><ul>
<li>股息强劲：3 只适合长期投资的蓝筹股</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analysts' expectations of $15.58 billion. During the same period last year, the business earned $3.00 EPS. The company's revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 10 月 31 日发布了季度财报。该公司报告每股收益为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。艾伯维的净利润率为 4.00%，股本回报率为 3,216.47%。该公司在本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。去年同期，该公司的每股收益为 3.00 美元。与去年同期相比，该公司的收入增长了 9.1%。艾伯维已将 2025 年第四季度的指导目标设定为每股收益 3.320-3.360 美元。研究分析师预计艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
</div><h2>AbbVie Increases Dividend</h2>
<div class="lb-trans"><h2>艾伯维增加股息</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is an increase from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie's dividend payout ratio is presently 496.97%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得 1.73 美元的股息。这比艾伯维之前的季度股息 1.64 美元有所增加。这代表着每年 6.92 美元的股息，收益率为 3.1%。该股息的除息日期为 1 月 16 日（星期五）。艾伯维的股息支付比率目前为 496.97%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
</div><p>ABBV has been the topic of a number of recent research reports. DZ Bank downgraded AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Citigroup lowered their price objective on shares of AbbVie from $240.00 to $235.00 and set a &#34;neutral&#34; rating for the company in a research note on Monday, November 3rd. BMO Capital Markets increased their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, September 12th. Erste Group Bank lowered shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, October 14th. Finally, JPMorgan Chase &amp; Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $245.84.</p>
<div class="lb-trans"><p>艾伯维最近成为多份研究报告的主题。DZ 银行将艾伯维的评级从 “买入” 下调至 “持有”，并设定了 237.00 美元的股票目标价。在 11 月 4 日（星期二）的研究报告中。花旗集团将艾伯维的目标价从 240.00 美元下调至 235.00 美元，并在 11 月 3 日（星期一）的研究报告中对该公司给予 “中性” 评级。BMO 资本市场将艾伯维的目标价从 215.00 美元上调至 240.00 美元，并在 9 月 12 日（星期五）的报告中给予该股票 “跑赢大盘” 评级。Erste 集团银行在 10 月 14 日（星期二）的报告中将艾伯维的评级从 “买入” 下调至 “持有”。最后，摩根大通将艾伯维的目标价从 250.00 美元上调至 260.00 美元，并在 11 月 3 日（星期一）的研究报告中给予该股票 “增持” 评级。三位分析师对该股票给予 “强烈买入” 评级，十三位给予 “买入” 评级，八位对该公司的股票给予 “持有” 评级。根据 MarketBeat.com，该股票目前的平均评级为 “适度买入”，共识目标价为 245.84 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on AbbVie</strong></p>
<div class="lb-trans"><p><strong>查看我们对艾伯维的最新分析</strong></p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于艾伯维</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过艾伯维</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>投资石油股票的方式和原因</li>
<li>忘掉芯片：4 只工业股在人工智能反弹中的表现</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 ABBV 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 AbbVie Inc. (NYSE:ABBV - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 AbbVie 吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 AbbVie 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 AbbVie 并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 AbbVie 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Patriot Financial Group Insurance Agency LLC 提高了其在艾伯维公司 $ABBV 的持股比例